Imatinib Cipla

Imatinib, the active ingredient in Imatinib Cipla, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is used to treat chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients. It is indicated for adult patients with these malignancies and is administered under specialist supervision.

GNH USA supplies Imatinib Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable global logistics.

Imatinib acts on malignant cells driven by specific tyrosine kinase pathways, providing targeted therapy for several hematologic and solid tumours.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): helps achieve remission and disease control. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and prolongs progression‑free survival.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Edema - Fatigue - Diarrhea

Serious or Rare Side Effects: - Neutropenia - Hepatotoxicity - Cardiac failure - Severe skin reactions (Stevens‑Johnson syndrome)

When prescribing Imatinib, clinicians should observe several safety measures to minimise risks. - Monitor blood counts: perform regular complete blood count assessments to detect neutropenia or thrombocytopenia. - Assess liver function: check hepatic enzymes periodically for signs of hepatotoxicity. - Evaluate cardiac status: conduct baseline and periodic ECGs in patients with cardiac risk factors. - Avoid use in patients with known hypersensitivity: discontinue if allergic reactions occur. - Store at room temperature: keep tablets in the original packaging, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise Imatinib levels and risk serious toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower Imatinib exposure, reducing therapeutic effect. - Anticoagulants (e.g., warfarin): Imatinib can enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors (e.g., omeprazole): may modestly affect absorption. - Azole antifungals (e.g., fluconazole): can increase Imatinib concentrations. - Macrolide antibiotics (e.g., erythromycin): may raise drug levels. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for additive gastrointestinal irritation.